DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Hämatologische Neoplasien » Multiples Myelom

Alle Linien

CARTITUDE-2
A Phase 2, Multicohort Open-Label study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy directed against BCMA in Subjects with Multiple Myeloma (68284528MMY2003) (Aktiv)

CC-92480-MM-002
A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) (Aktiv)

Erstlinie

AGMT_MM-2
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy (Aktiv)

CARAMBA-1
A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells (Aktiv)

CONCEPT
Study evaluating induction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in multiple myeloma (Aktiv)

DREAMM9 (GSK 209664))
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (Aktiv)

Paraproteinämische Keratopathie
Inzidenz der paraproteinämischer Keratopathie bei Patienten mit monoklonaler Gammopathie unklarer Signifikanz, smoldering multiplem Myelom und multiplem Myelom (Aktiv)

TALMMY 1001-PT3,JNJ-64407564MMY1001
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (Aktiv)

Zweitlinie oder später

64407564MMY1005 TRIMM-3
A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (Aktiv)

AGMT_MM1
Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma (Aktiv)

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma
At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia (Aktiv)

AMG 70120170122
The purpose of this First-in-Human Phase 1 study is to determine during the escalation part if AMG 701 given as weekly short term IV infusions is safe and tolerable followed by a dose expansion part to gain further efficacy and safety experience with AMG 701 in adult subjects with relapsed / refractory multiple myeloma (Aktiv)

CC-220-MM-001
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (Aktiv)

CC-4047
Study at several sites to evaluate pomalidomide taken with dexamethasone (low dose) in patients with Multiple Myeloma (MM) and impaired kidney function who did not respond to the previous treatment or whose disease has returned after the previous treatment (Aktiv)

DREAMM5 (GSK 208887)
Platform Study of GSK2857916 as monotherapy and in combination with anti-cancer treatmentsin participants with RRMM (Aktiv)

EMN-alloRIC
Improve the efficacy and outcome after transplant of patients with hematologic malignancies (phase I trial) and multiple myeloma (phase II trial) (Aktiv)

GC-LTFU-001
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)

LYNX (54767414MMY2065)
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) (Aktiv)

MAGE-A1
Eine Phase-I-Studie mit MAGE-A1-spezifischen TCR-veränderten T-Zellen (Aktiv)

Masitinib, AB06002
Study to Compare Efficacy and Safety of Masitinib in Patients With Relapsing Multiple Myeloma (Aktiv)

Novartis CWVT078A12101
A Study of WVT078 in Patients With Multiple Myeloma (MM) (Aktiv)

PCYC-1138-CA
Study of Ibrutinib in Combination with Pomalidomide and Dexamethasone (Aktiv)

Paraproteinämische Keratopathie
Inzidenz der paraproteinämischer Keratopathie bei Patienten mit monoklonaler Gammopathie unklarer Signifikanz, smoldering multiplem Myelom und multiplem Myelom (Aktiv)

TALMMY1001-PT3
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma (Aktiv)

TECLIMMY 10001-P3,JNJ-64007957MMY1001
A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (Aktiv)

TRIMM-2, 64407564MMY1002
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de